EHSI: Stem Cell ‘On Switch’ May Have Been Found

Emerging Healthcare Solutions Energized by Recent Discovery

HOUSTON--(BUSINESS WIRE)-- Emerging Healthcare Solutions, Inc. was energized Monday by news that researchers in North Carolina may have identified the gene activator that allows stem cells to reproduce and become any type of cell in the body.

The Charlotte Observer reported on Sunday that UNC Chapel Hill professor Yi Zhang had identified a protein known as Tet 1 to be the “on switch” within each stem cell. According to the Observer, Tet 1 activates a gene called Nanog that allows stem cells to reproduce while maintaining their pluripotency. Understanding the interaction between Tet 1 and Nanog could unlock the secrets to transforming one kind of mature cell into another.

“This represents another potential breakthrough in the field of stem cell research,” said Cindy Morrissey, President and CEO of Emerging Healthcare Solutions. “If a method can be developed to regress human cells back into stem cells and then into other types of cells, the potential to produce new liver cells, new pancreas cells, and any number of others might truly revolutionize the practice of medicine.”

Such a method would not require the use of embryonic stem cells, neatly side-stepping the ethical debate surrounding their use.

The Observer reported that researchers will keep watch over cells reprogrammed with Tet 1 to see if their life span mirrors that of natural stem cells or if they instead become malignant. Emerging Healthcare Solutions keeps a close eye on stem cell research worldwide. In March, the company signed a profit participation deal with Celulas Genetica, a biotech firm dedicated to developing radically new medical solutions using adult stem cell research.

EHSI invests in technology developed to compete in the stem-cell research industry alongside Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corp. (NASDAQ: CELG), Astrazeneca PLC (NYSE: AZN) and Genzyme (NASDAQ: GENZ). The biotechnology sector also includes Biogen Idec (NASDAQ: BIIB).

About Emerging Healthcare Solutions, Inc.

Emerging Healthcare Solutions, Inc. invests in and participates in the profits of emerging breakthrough medical technologies. The Company believes the secret of leveraging future value for its shareholders is the proper timing of its investment in promising new medical technologies. EHSI aims to capture future profits of promising new medical technologies by investing in these technologies at the inflection point of product development. We believe this model will deliver long-term positive results for our investors.

For more information, please visit http://www.EmergingHealthcareSolutionsInc.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.



CONTACT:

Emerging Healthcare Solutions, Inc.
Cindy Morrissey, 713-821-1486
President and CEO

KEYWORDS:   United States  North America  North Carolina  Texas

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Genetics  Medical Devices

MEDIA:

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.